News & Updates
Filter by Specialty:
Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab
The use of lebrikizumab improves the symptoms of moderate-to-severe atopic dermatitis (AD) in patients previously treated with dupilumab, reports a study presented at AAD 2025.
Lebrikizumab relieves itch, skin pain in AD patients previously on dupilumab
28 Mar 2025
Eyebrow or eyelash hair loss affects QoL in AA patients
A real-world analysis presented at AAD 2025 shows that patients with alopecia areata (AA) with eyebrow or eyelash hair loss have greater health-related quality of life (HRQoL) burden than those without eyebrow and eyelash involvement.
Eyebrow or eyelash hair loss affects QoL in AA patients
25 Mar 2025
Composite metric boosts tapinarof efficacy for AD
Two pivotal phase III trials show that a once-daily application of tapinarof cream 1% yields rapid treatment response – as indicated by the vIGA-AD™×BSA* composite score – in individuals with moderate-to-severe atopic dermatitis (AD).
Composite metric boosts tapinarof efficacy for AD
20 Mar 2025
Dupilumab eases itch, disease activity in chronic spontaneous urticaria
Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.